Details of the Drug-Related molecule(s) Interaction Atlas

BZ-55 Drug Info

Alentin; Aminophenurobutane; Bucarban; Bucrol; Bukarban; Burcol; Butisulfina; Carbutamid; Carbutamide; Carbutamide [INN:BAN]; Diabetin; Diabetoplex; Diaboral; Diabutan; Emedan; Glucidoral; Glucofren; Glybutamide; Inbuton; Invenol; N'-(Butylcarbamoyl)sulfanilamide; N-Butyl-N'-sulfanilylurea; N-Butylsulfanilylurea; N-Sulfanilyl-N'-butylurea; Nadisan; Nadizan; Norboral; Oranil; Oranyl; Orasulin; Sulfonamide carbutamide; Urea, 1-butyl-3-sulfanilyl-; 1-BUTYL-3-SULFANILYLUREA; 339-43-5; 4-amino-N-[(butylamino)carbonyl]benzenesulfonamide; BZ 55

Cross-matching ID

PubChem CID

9564

ChEBI ID

CHEBI:135118

CAS Number

CAS 339-43-5

TTD Drug ID

DMH6B9J

INTEDE Drug ID

DR0274

General Information of Drug (ID: DMH6B9J)

Molecule-Related Drug Atlas

Molecule Type:

DME

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[2]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[3]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[4]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[5]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[6]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[5]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[7]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[9]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug-Metabolizing Enzyme (DME)

References

1	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
2	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
3	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
4	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
5	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
6	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
7	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
8	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
9	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
10	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.